Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Regeneron Forges Out-of-the-Box R&D Pact With Boston's Decibel Therapeutics November 28, 2017 What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets June 26, 2017 New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson September 20, 2017
New Kid on the Block Provention Bio Snags 2 Clinic-Ready Immune Compounds From Johnson & Johnson September 20, 2017
